Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of GV20-0251 combined with an anti-PD-1 antibody in unresectable, locally advanced, or metastatic solid tumors
CTR20261879Phase 2Active
- Sponsor
- SeekIn
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GV20-0251 in Nonhematologic neoplasms, endometrial cancer (EC), Cervical Cancer (CC) and 12 more, sponsored by SeekIn. Primary endpoints: Dose-limiting toxicity and treatment-emergent adverse events and Objective response rate. Started Jun 2026; status: active.
02
Drugs
GV20-0251
03
Conditions
Nonhematologic neoplasmsendometrial cancer (EC)Cervical Cancer (CC)ovarian cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20261879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261879.